We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

23 hedge funds and large institutions have $2.05M invested in Faeth Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more funds holding

Funds holding: 21 → 23 (+2)

0.01% more ownership

Funds ownership: 0.58% → 0.59% (+0.01%)

14% less capital invested

Capital invested by funds: $2.38M → $2.05M (-$331K)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
23
Holders Change
+2
Holders Change %
+9.52%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$40.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$17.6K
3
TRCT
Tower Research Capital (TRC)
New York
+$805
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$205
5
Morgan Stanley
Morgan Stanley
New York
+$150

Top Sellers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
-$156K
2
Millennium Management
Millennium Management
New York
-$13K
3
Two Sigma Investments
Two Sigma Investments
New York
-$478
4
BlackRock
BlackRock
New York
-$273
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$273
Name Holding Trade Value Shares
Change 		Change in
Stake
NM
1
Newtyn Management
New York
$1.09M -$156K -11,399 -13%
Vanguard Group
2
Vanguard Group
Pennsylvania
$397K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$99K +$40.7K +2,985 +71%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$94.3K – – –
BCM
5
Bridgeway Capital Management
Texas
$78.1K – – –
DFO
6
Duquesne Family Office
New York
$69K – – –
Bank of America
7
Bank of America
North Carolina
$62.8K – – –
Millennium Management
8
Millennium Management
New York
$26.5K -$13K -950 -33%
BlackRock
9
BlackRock
New York
$24.1K -$273 -20 -1%
Northern Trust
10
Northern Trust
Illinois
$18K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$17.9K +$17.6K +1,290 New
State Street
12
State Street
Massachusetts
$17.8K – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$13.1K -$273 -20 -2%
LWL
14
Leo Wealth LLC
Texas
$10.3K +$10.1K +742 New
RJA
15
Raymond James & Associates
Florida
$9.69K – – –
DCM
16
Deuterium Capital Management
Florida
$7.61K – – –
Two Sigma Investments
17
Two Sigma Investments
New York
$7.04K -$478 -35 -6%
TRCT
18
Tower Research Capital (TRC)
New York
$5.84K +$805 +59 +16%
BCV
19
Banque Cantonale Vaudoise
Switzerland
$3K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$462 – – –
Morgan Stanley
21
Morgan Stanley
New York
$302 +$150 +11 +100%
Wells Fargo
22
Wells Fargo
California
$91 – – –
Qube Research & Technologies (QRT)
23
Qube Research & Technologies (QRT)
United Kingdom
$3 – – –
HI
24
Harbour Investments
Wisconsin
– -$2 – –
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– +$205 +15 +125%

FTH Hedge Fund Activity: Q4 2023 in Review

23 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q4 2023, worth a combined $2.05M — down 14% from $2.38M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new FTH positions and 0 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $40.7K. The largest seller was Newtyn Management, cutting an estimated $156K.

  • 23 institutional investors held Faeth Therapeutics (FTH) as of Q4 2023, up from 21 in Q3 2023.
  • Funds reported $2.05M of Faeth Therapeutics stock for Q4 2023, down 14% quarter-over-quarter.
  • 2 funds opened new Faeth Therapeutics positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest Faeth Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $40.7K added.
  • The largest Faeth Therapeutics seller in Q4 2023 was Newtyn Management, an estimated $156K sold.

Based on aggregated 13F filings for Q4 2023.